八大胜

About Us
Domestic layout
Strategic layout

We implement the 2027 "Ten, Hundred, Thousand" development strategy, that is, achieve "cumulative revenue reaching 1 billion, group valuation reaching 10 billion, and number of employees reaching 1,000" by 2027, and strive to become a leading enterprise in the field of cell and gene therapy (CGT) in China.

Guangdong First Condor Biotechnology Co., Ltd
  • Shenzhen First Condor Life Science Co., LTD.
    To conquer solid tumors as the enterprise mission, to develop cell drugs (CAR-T, CAR-NK, TIL, etc.), antibody drugs, gene drugs, etc.
  • Dongguan Life Bank
    Based on the Songshan Lake (First Condor) comprehensive cell Bank, based on Dongguan and facing the whole country, it focuses on the storage of neonatal umbilical cord / placental stem cells and adult immune cells.
  • Dongguan Zalijan Biotechnology Co., LTD.
    Based on the Songshan Lake (First Condor) Regional Cell Preparation Center, it is committed to the research of stem cells and regenerative medicine and the modernization, standardization and large-scale production of clinical-grad cell products.

  • First Condor Gene Therapy Company (in preparation)

    The company uses a know-how-based R&D strategy to find new treatment targets, starting with motor neurone disease and gradually expanding to gene therapy and translational research for other neurodegenerative diseases. It plans to apply for 2-4 patents or orphan drugs, and transform new drug research and development into clinical trials and clinical applications.



Industrial Distribution
Industrial Distribution
  • Cell storage
  • Cellular drugs
  • Regenerative medicine
  • Cell derivatives
  • CDMO service
  • Cell Quality Assay